Many in Congress think the government needs to set stricter rules to prevent health insurers’ from slow-walking decisions on whether to approve treatments. But representatives hit a snag last year after their bill to tighten up the “prior authorization” process breezed through the House because senators were concerned about the measure’s projected $16 billion cost.
